Helping to improve your quality of life.
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, sexual dysfunction and CNS disease. The company selects drugs from its extensive portfolio with the potential to be safe and effective for improving patient care while significantly increasing near-term value for partners and payers. The product pipeline includes new uses for previously approved drugs, some of which are now starting clinical trials, and new molecular entities (“NMEs”).
A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize the company’s product development programs. Learn More
Diagnostic Product Pipeline
| DIAGNOSTIC | Discovery | Instrumentation Development | Clinical Trials | Regulatory | Commerciali- zation |
|---|---|---|---|---|---|
| ORP Cardiac |
|||||
| ORP CNS |
|||||
| ORP Critical Care |
|||||
Learn More About:
Premature Ejaculation (PE)
Premature ejaculation is a distressing male sexual dysfunction that is more common than erectile dysfunction (ED) and has a major impact on the quality of life for men and their sexual partners.
Diabetic Retinopathy
A complication of diabetes mellitus that damages the retina in the eyes and leads to blindness
Diabetic Nephropathy
A progressive complication of diabetes mellitus that leads to end-stage renal disease (ESRD) requiring kidney transplantation or chronic dialysis
| AMPE Stock Quote - delayed | ||
| Last | Change | |
| AMPE | 2.85 |  0.12 (4.40%) |
Ampio News
05/14/2012 | Press Release
Ampio Pharmaceuticals Schedules 2012 Update Webcast
05/11/2012 | Press Release
04/30/2012 | Press Release